Valeant Finds Buyer for Skin-Care Biz

Jul 18, 2017

Valeant Pharmaceuticals has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash, as part of the Canadian drugmaker's efforts to cut down its debt.

Valeant, which acquired the California-based Obagi for about $344-million in 2013, will sell the business to Haitong International Zhonghua Finance Acquisition Fund I LP. Limited partners of the Haitong fund include industry veterans, China Regenerative Medicine International.

Obagi is a specialty pharmaceutical company that develops, markets, and sells topical aesthetic and therapeutic skin-care products.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments